Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challengesMiguel García-Pardo, Natasha B. Leighl, Maisam Makarem et al.|British Journal of Cancer|2022Cited by 112
Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung CancerMiguel García-Pardo, Natasha B. Leighl, Kasia Czarnecka‐Kujawa et al.|JAMA Network Open|2023Cited by 60
Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiologyJuan Carlos Laguna, Laura Mezquita, Miguel García-Pardo et al.|Therapeutic Advances in Medical Oncology|2024Cited by 48
Respiratory and Cardiometabolic Comorbidities and Stages I to III NSCLC Survival: A Pooled Analysis From the International Lung Cancer ConsortiumMiguel García-Pardo, Geoffrey Liu, Matthew B. Schabath et al.|Journal of Thoracic Oncology|2022Cited by 26
Vaccine Therapy in Non-Small Cell Lung CancerMiguel García-Pardo, Laura Mezquita, Teresa Gorría et al.|Vaccines|2022Cited by 23